Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Kontafarma China Holdings Ltd ( (HK:1312) ).
Kontafarma China Holdings Ltd has announced an extraordinary general meeting to approve a construction contract for a new R&D complex in Beijing. This development signifies the company’s commitment to expanding its research capabilities, potentially enhancing its market position and offering growth opportunities for stakeholders.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd operates in the pharmaceutical industry, focusing on the development and construction of research and development facilities through its subsidiary, Tongfang Pharmaceutical Group Co., Ltd.
Average Trading Volume: 4,554,413
Technical Sentiment Signal: Sell
Current Market Cap: HK$167.4M
For detailed information about 1312 stock, go to TipRanks’ Stock Analysis page.